Primary endpoint of time to substantial symptom resolution was not met in acutely symptomatic, non-hospitalized COVID-19 patientsCNM-ZnAg treatment was safe…
-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25…
PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27,…
HOUSTON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Modern Vascular, the national leader in minimally invasive treatment for Peripheral Artery Disease…
New Line of Protein Bars Specifically Formulated with the Greens First PRO Line, Provides a Nutrient Dense Meal Replacement with…
New Indications Include Use with a Broad Class of Commercially Available Rods iFuse Bedrock Granite® iFuse Bedrock Granite® SANTA CLARA,…
New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that,…
SINGAPORE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Ltd. (“ALRT”) (OTCQB:ALRTF), the diabetes management company, today announced the…
Initial $3.5M Funding Maintains Cash Runway of Mid-2023SAN DIEGO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a…
TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced…